ST. LOUIS, May 24 /PRNewswire/ -- ZeaVision, LLC has introduced a proprietary program for Eye Care Professionals that can quickly and easily assess risk for Age-Related Macular Degeneration (AMD). Currently available only in the St. Louis market, ZeaVision expects to introduce this program, called QuantifEYE(TM), nationally, with plans to expand into key European markets starting in 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060524/ZEAVISIONLOGO )
AMD is fast reaching epidemic proportions with 15 million Americans currently affected. That number is expected to double by 2020 as Baby Boomers reach their 60’s and 70’s. AMD is a disease affecting the macula in the retina of the eye, and is the leading cause of blindness in this age group. Once symptoms are noticeable, damage has already occurred. AMD’s effects are both permanent and irreversible.
ZeaVision’s QuantifEYE Program is the first of its kind in the world to quickly, conveniently, and inexpensively identify potential risk of AMD (and other diseases of the eye). The QuantifEYE Program, through early detection and mitigation of risk for AMD, has potential to significantly reduce Medicare costs for a disease that is growing in scope and burden. Doctors can screen patients at an early age and can now monitor Macular Pigment Optical Density (MPOD) levels as part of their eye care routine. Low macular pigment has been associated with high risk for AMD. The device being introduced can measure pigment in the macula -- something only available at research facilities -- until now.
For patients that are found to have low levels of macular pigment, suggesting a change in diet along with zeaxanthin- and lutein-based supplements can positively impact risk. Prevention is key, and early risk identification can make the difference in their patients’ quality of life.
ZeaVision, LLC, a St. Louis-based company, founded in December, 2000, is committed to leading the fight against vision loss associated with Macular Degeneration. Dennis Gierhart, Ph.D., Chairman and CEO/CSO, has dedicated the last 20 years to research and development of products and services for prevention of AMD.
For more information, contact: Rachel Voss, Public Relations Manager ZeaVision, LLC 314.628.1000 rvoss@zeavision.com
Photo: http://www.newscom.com/cgi-bin/prnh/20060524/ZEAVISIONLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comZeaVision, LLC
CONTACT: Rachel Voss, Public Relations Manager of ZeaVision, LLC,+1-314-628-1000, rvoss@zeavision.com
Web site: http://www.eyepromise.com/
